CA-CLICKHOUSE
30.7.2024 16:01:35 CEST | Business Wire | Press release
ClickHouse, Inc., the company behind the world’s fastest and most popular real-time analytical database, is thrilled to announce the acquisition of PeerDB, a leading provider of change data capture (CDC) solutions for Postgres databases. This strategic acquisition underscores ClickHouse’s commitment to delivering unparalleled real-time analytics and data integration capabilities to its customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240730221289/en/
ClickHouse acquires PeerDB to boost real-time analytics with Postgres CDC integration (Graphic: Business Wire)
PeerDB’s technology significantly reduces the time it takes to connect data in transactional databases like Postgres with analytical databases like ClickHouse, boosting developer productivity and time-to-value when building real-time data driven applications. With PeerDB CDC technology integrated into ClickHouse Cloud, users will benefit from seamless, real-time data replication from Postgres databases to ClickHouse.
“We are excited to welcome PeerDB into ClickHouse,” said Aaron Katz, CEO of ClickHouse, Inc. “This acquisition aligns with our mission to empower our customers with the most advanced and efficient data analytics solutions. By integrating PeerDB’s CDC technology, we are empowering Postgres developers to move even faster when building real-time data driven applications. Now, all they have to do is configure a mirror between their existing Postgres databases and ClickHouse, and the data is available for lightning-fast analytical queries.”
Sai Krishna Srirampur, CEO of PeerDB, expressed his enthusiasm for what the future holds, stating, “We are thrilled to join forces with ClickHouse. This acquisition is a natural evolution for us at PeerDB, as we already share many joint enthusiastic users with ClickHouse. Postgres is becoming the de facto operational database, while ClickHouse is the fastest analytical database on the planet. Both originate from the same open-source ethos. This acquisition bridges the gap between Postgres and ClickHouse, enabling businesses to seamlessly move their operational data for real-time analytics.”
Javier Erro Garcia, Cloud Architecture Manager at Vueling Airlines, shared excitement about the upcoming integration: “As a user of both ClickHouse Cloud and PeerDB, I am thrilled about this acquisition. We already reduced our Postgres to ClickHouse snapshot times from 10+ hours down to 15 minutes with PeerDB. Combining ClickHouse’s powerful analytics natively with PeerDB’s real-time data capture capabilities will greatly simplify our data processing workflows. This integration will enable us to build analytical applications faster, giving us a competitive edge in the market.”
The combined expertise of ClickHouse and PeerDB will pave the way for the development of new features and capabilities aimed at meeting the evolving needs of data-driven enterprises. Customers can look forward to deeper integration between PeerDB Cloud and ClickHouse Cloud and support for additional CDC data sources. The ClickHouse technical blog post introducing the acquisition provides more detail.
About ClickHouse
ClickHouse is a fast, open-source, columnar OLAP database management system. It allows users to generate analytics using SQL queries in real-time. Designed to analyze large volumes of data, ClickHouse is used by industry leaders around the globe for its unmatched performance, scalability, and reliability.
About PeerDB
PeerDB is a leading provider of change data capture (CDC) solutions for Postgres databases. Their technology enables real-time data replication and synchronization, helping businesses keep their data up-to-date and accessible for analytics and decision-making processes.
PeerDB was founded by Kaushik Iska and Sai Srirampur in mid 2023 and has since grown to become a leading Postgres data replication company in the market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730221289/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom